Mr. Feng is a partner based in Haiwen Beijing office. Mr. Feng has over 18 years of legal experiences, and has been deeply trusted and recognized by his clients. Mr. Feng’s practice area mainly focus in PE investment, cross-border M&A, life sciences & healthcare and corporate compliance, etc.
Mr. Feng joined Haiwen in 2019 as partner. Before joining Haiwen, he worked from 2017 to 2018 in Zenity Holdings as General Counsel and in Zenity Capital as Vice President in charge of the overall legal management of the company and its listed and non-listed subsidiaries, supporting the investment and financing of the listed company in issuing additional shares, establishing industrial funds, implementing major asset restructuring, and investing in and financing new production lines. From 2003 to 2017, Mr. Feng worked at Beijing office of JunHe LLP and represented a great number of multinational companies, Chinese enterprises and private equity funds in their acquisition, joint venture, private equity investment, restructuring and divestment projects. Mr. Feng specializes in providing comprehensive legal services to clients in large-scale Sino-foreign equity joint venture projects and complex cross-border M&A transactions, including structuring, transaction document drafting and negotiation, closing process control and the related legal consultations in M&A deals. Mr. Feng’s specialty extends to various different sectors including life sciences & healthcare, automotive, TMT and aviation, etc.
In the area of investment and M&A transactions, Mr. Feng has extensively represented private equity investment institutions such as Hillhouse Capital, CVC, HM Capital, Baidu Ventures, 3E Bioventures, CDH Capital, Shougang Fund, JAC Capital and Wise Road Capital, etc. in their investment projects, represented enterprises such as Baiwang, BeiGene, VDO Biotech, InxMed, Autel, Talent Cradle Edu, Royal Seal Group and Brilliance Auto, etc. in their equity financing, investments, divisions and restructurings, represented multinational companies such as Shell, Dow Chemical, GE Aviation, Philips, Cipla, Stora Enso, Daewoo, Maersk, QIAGEN, TK Elevator, Goodyear and BOC Insurance, etc. in their cross-border M&As, joint ventures or sales of equity/business, represented Tianjin Free Trade Zone and Guangdong Pilot Free Trade Zone in their introducing milestone investment projects such as Airbus and Tesla, provided general or special legal consultations for enterprises such as Merck, BMW Brilliance, Volkswagen China, Intel, VIPKID, Eli Lilly and Varian, etc. Mr. Feng’s recent experiences include representing Hillhouse Capital in its investment in Junlebao Milk and MXBC, representing client in the merger of VDO Biotech, BeamDiag and QuantoBio Biotech, representing Baiwang in its several rounds of equity financing, representing various investors in numerous automotive AI projects, representing JAC Capital in its joint venture project with Qualcomm and Datang Telecom in the mobile phone SoCs, representing Shell in the sale of its equity interest in Tongyi Oil to Carlyle, representing SGCH China Holding in selling out its equity interest in ChinaHR to 58.com, and representing Dow Chemical in the restructuring of Chinese business as a part of its global merger with DuPont.
In the sector of life sciences and healthcare, Mr. Feng has represented InxMed in the acquisition of U.S. biopharmaceutical R&D assets and the license-in transaction with Oncomatryx, represented BeiGene in its joint venture project with Guangzhou Development Zone regarding PD-1/PD-L1 oncology biopharmaceutical manufacturing, represented Cipla of India in selling out its equity interest in a Chinese pharmaceutical joint venture, represented Ping An Trust in the financing of Innovent, represented Huapont Health in series D investment in a US biopharmaceutical company, represented Royal Seal Group investing in an oncology start-up led by Professor CHEN Lieping, represented Philips in its divestment project with respect to a medical imaging equipment manufacturing joint venture and the transfer of a part of research assets, represented QIAGEN in establishing a joint venture company with Maccura for manufacturing and distribution of Gene Reader devices.
In the area of corporate compliance, in addition to routine compliance consulting work, Mr. Feng has assisted a central SOE handling the cross-debarment sanctions initiated by Africa Development Bank, and represented Shaklee in handling direct sales compliance investigations conducted by the Administration for Market Regulation.
Mr. Feng was awarded as one of the “15 Rising Stars of China Lawyers” in 2016 by the Asian Law and Business (ALB).
Mr. Feng received his LL.B. degree and his Master of Laws degree from the Law School of Peking University in 1999 and 2003, respectively, and his LL.M. degree from the School of Law, New York University in 2003.
Mr. Feng’s native language is Mandarin, and he speaks English fluently.
Beijing ICP No. 05019364-1 Beijing Public Network Security 110105011258
